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ABSTRACT. Biotechnology has initiated a profound revolution in science with enormous technological and
social consequences. The next 15 to 20 years will see biotechnology playing an increasingly important role in
society in general. It will have impacts in the areas of human health, animal nutrition and plant agriculture.
There will be 9 billion people on earth in 2025, and all the resources associated with biotechnology will be
needed to enhance life in the next century.
It is generally accepted that the first successes of biotechnology will be in the areas of human health. Recent
discoveries suggest that during the next 15 to 20 years, biotechnology may shift the central thrust of medicine
from treatment to prevention.
One of the first biotechnology products in the animal nutrition area that is likely to enjoy widespread use
will be bovine somatotropin (BST) to help improve milk production and feed efficiency in dairy cows. Within
the next decade, genetic engineering will also confer desirable properties on plants such as resistance to pests,
pathogens and, finally, environmental stress.
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INTRODUCTION
What might the next 10-15 years of biotechnology
have in store for society in general and especially in the
field of agriculture? Such speculation always involves
risk. The National Academy of Sciences and the National
Research Council have made 5- and 10-year predictions
since the mid-1930s which missed, among other things,
antibiotics, nuclear energy, microprocessors, and mo-
lecular biology. However, speculation does serve a useful
purpose: it enables the public to decide whether opening
the door of biotechnology will lead to a wealth of new
products or a mere handful of interesting curiosities.
This paper will discuss briefly some impacts of bio-
technology on human health and on animal nutrition and
health. It will then examine the potential impact of
biotechnology and its intellectual core, molecular biol-
ogy, on agriculture. It will also suggest some ways in
which we can shift the central thrust of plant protection
from treatment to prevention. Finally, it will comment
on potential applications of biotechnology in the produc-
tion of commodity chemicals and the potential use of
biomass (e.g., plant wastes and cellulose) as a source of
energy or raw materials.
DISCUSSION
BIOTECHNOLOGY. What is biotechnology? Why all
the excitement? What does biotechnology have in store
for science and society in general over the next 15 years?
The term biotechnology will be used to denote these
processes: 1) use of microorganisms, plant cells, animal
cells, or parts of cells such as enzymes to produce com-
mercial quantities of useful substances; 2) construction
of microorganisms, cells, plants, or animals with useful
traits by recombinant DNA techniques, cell fusion,
and other methods besides traditional genetic breeding
techniques; 3) the application of molecular biology
to understanding how cells and organisms work, so
that the activities of cells and organisms can be altered
or repaired.
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The "bio" part of biotechnology is principally molecu-
lar genetics, microbiology, biochemistry (especially pro-
tein chemistry), and immunology. The "technology"
part is largely chemical engineering, especially fer-
mentation engineering, separation technology, and the
like. Although the "bio" part of biotechnology (i.e., the
genetic engineering) receives greater public attention
than chemical engineering, it is only a part of the total
technological package. A good part of biotechnology,
when it is practiced in industry, will be conducted by
chemical engineers or, more precisely, by biochemical
engineers experienced in fermentation, who know how to
extract 1 kg of fastidiously pure protein from 100,000L
of a dilute fermentation soup.
Although this paper focuses on the genetic engineer-
ing part of biotechnology, the scenarios that are outlined
demand that biochemical engineering move forward at a
rapid pace during the next 15 years.
HUMAN HEALTH. Most biotechnology research today
is focused on human diseases. Hence, it is generally
accepted that the first successes of biotechnology will be
in producing proteins and peptides for human therapy.
Molecular biologists have redesigned bacteria genetically
to make substances native only to humans. Some well
known products now being developed for applications to
people include growth hormones, interferons (alpha,
beta, gamma), interleukins, hormone-releasing factors,
neuroactive peptides, and immunosuppressive factors.
Blood components also have been developed. These
include clotting factors (for hemophilia), clot-dissolving
factors (plasminogen activators — initially for treatment
but eventually prophylaxis for strokes and heart attacks),
human serum albumin, and anticoagulant factors.
Atriopeptigen is one of the most exciting new products
under study. It was reported by a joint drug discovery
team comprised of Washington University (St. Louis)
and Monsanto Company scientists (Cole et al. 1984). The
mammalian heart, strange to say, is a major endocrine
organ. The cardiac atria can synthesize and release several
biologically active peptides that exert profound effects on
sodium excretion, urine volume, and smooth muscle tone
and cause selective renal vasodilation.
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It is likely that by the end of the decade the atrial
peptides and most of the other products mentioned will
have been clinically evaluated in humans, and several will
be in general use. However, for many of these powerful
biologically active materials (e.g., peptides and proteins
active at the picogram level), the most important ther-
apeutic uses may not yet have been uncovered.
An important class of proteins and peptides that will
also receive increasing attention during the next decade
is broadly termed the neuropeptides. These include en-
dorphins, enkephalins, gastrin, and others. A veritable
arsenal of peptides and proteins produced by the
human brain and by other organs have specific parts of
the brain as their target and can profoundly alter pain,
anger, appetite, satiety, sexuality, and many other ele-
ments of behavior. Unlike nerve transmitters such as
acetylcholine, by which one cell affects its immediate
neighbor cells, these neuropeptides affect millions of
cells in specific areas of the brain and alter mood, desire,
and motivation.
As soon as molecular biologists have produced ade-
quate quantities of various neuropeptides, their effects
and potential therapeutic uses will be analyzed by neu-
rochemists and neurobiologists. It is likely that some will
prove to be important therapeutic agents in themselves.
It is almost certain that their study will lead us to an
understanding of the molecular causes of and cures for
crippling mental diseases such as schizophrenia, depres-
sion, and Alzheimer's disease, as well as causes of and
cures for addiction.
Insights into deep-rooted causes of human cancer are
also being gained. Potential for the disease appears to
lurk within all of us; normal cellular genes can quickly be
changed into cancer-causing agents known as oncogenes.
The development of vaccines and other therapies for
the great parasitic plagues of mankind can also be antici-
pated. Malaria and the trypanosome-caused diseases (i.e.,
sleeping sickness and Chagas disease) are under surveil-
lance and attack by molecular biologists and medical
entomologists. Considerable progress is being made in
the development of genetically engineered vaccines for
malaria and for the trypanosome-caused diseases.
Novel strategies have been devised to overcome the
ability of protozoan parasites to evade human immune
defenses by secreting new coat proteins and other tricks.
There is also the likely prospect that filariasis, schis-
tosomiasis, and other diseases caused by parasitic worms
will succumb to novel attack by molecular biologists and
immunologists. Indeed, there is a reasonable likelihood
that by 2000 A.D., these diseases will be controlled by
a vaccination. Malaria is likely to be the first to succumb,
then the trypanosomes and, finally and with difficulty,
the worms (National Science Board 1985).
In addition, it is likely that other products of bio-
technology will aid in providing early warning for various
diseases. Scientists have succeeded in isolating specific
DNA sequences that may predispose individuals to heart
disease and emphysema, and are searching for genes that
may predispose us to diabetes, allergies and peptic ulcers.
Discoveries of this kind suggest that during the next 15
to 20 years, biotechnology may shift the central thrust of
medicine from treatment to prevention.
Up to this point, the gene-splicing component of bio-
technology has been emphasized. Yet many scientists
believe that immunology will prove even more powerful
in human therapy. As the comprehension of the immune
system increases, the meaning of the "carbohydrate code"
will be understood just as the nucleic acid and protein
codes were unravelled. The biological significance of gly-
cosylation, which is so widespread in eukaryotic proteins,
will also be determined, as well as how therapeutic agents
can be targeted to specific organs. Perhaps monoclonal
antibodies will be used to clean up small numbers of
cancer cells that often persist after surgery, chemo-
therapy, or radiation. It may also be possible to selec-
tively control the immune response to transplanted
kidney, heart, skin and liver so that they are not readily
rejected. Diseases that will begin to succumb because
of these advances include many kinds of cancers,
autoimmune diseases, atherosclerosis, arthritis, and
many others.
ANIMAL HEALTH AND N U T R I T I O N . Since there
may be 9 billion people on earth in 2025A.D., a number
of strategies will be needed to enhance animal protein
production. The opportunities in animal health and
nutrition will be numerous. One of the first of the bio-
technology products likely to enjoy widespread use will
be bovine somatotropin. Extensive tests on dairy cows
have already shown that bovine somatotropin (e.g., a
peptide hormone) increases both milk production and
feed efficiency (i.e., more milk from the same amount of
feed). The development of vaccines produced by bio-
technology for foot and mouth disease, scours, shipping
fever, and other diseases of cattle and swine/ can also be
anticipated. As animals are raised under more crowded
conditions, they will become more susceptible to disease.
Genetic engineering of chickens, swine, and cattle is also
a possibility. They will be born already vaccinated and
resistant to diseases. It will also be possible to rapidly
accelerate animal breeding for feed efficiency, disease re-
sistance, and other desirable qualities (Olson 1986).
BIOTECHNOLOGY AND AGRICULTURE. Let us now
turn to the potential impact of biotechnology on plant
agriculture. Within the next decade or so, genetic engi-
neering will confer desirable properties on plants such as
resistance to environmental stress, pests, and pathogens
(Ross 1984). There is reason to believe that temperature
tolerance in various crops can be increased by the appli-
cation of genetic engineering. Endowing crops with
enhanced temperature tolerance will be a fantastic chal-
lenge. If the northern range of specific crops could be
extended, it would be possible to increase the produc-
tivity of millions of hectares throughout the world. At
these more northerly latitudes, crops are produced only
one or two years out of four because of the cold. Increased
drought tolerance in a crop would also be a major break-
through because hitherto non-cultivated land could be-
come productive for the first time. Crops could also be
made resistant to heat stress.
Learning to control a storage protein gene could also
lead to improved nutritional quality of seed grains. Simi-
lar work could serve to improve the nutritional quality
of taro, manioc, and other root crops by increasing pro-
tein content and decreasing naturally occurring cyanide
content.
Earlier maturation is another challenge. Plants that
mature earlier will alter planting and harvest cycles and
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improve farm income. Herbicide resistance also promises
to be of practical interest because it could couple cheap,
safe, general herbicides with herbicide-resistant crops.
There are also attractive opportunities to develop new
crop plant varieties that keep top soil in place.
CROPS RESISTANT TO INSECTS: PREVENTION INSTEAD
OF TREATMENT. Another prospect of plant biotechnol-
ogy is to produce crop species that are resistant to insect
attack. This would shift the central thrust of plant
protection from treatment to prevention. What novel
proteins and peptides should cotton, soybeans, and rice
synthesize to provide protection against insect pests?
What genes should be transplanted into a plant to endow
the plant with resistance to insects?
The pests of insect pests may well hold a clue. What
proteins and peptides do the viral, bacterial, fungal, and
multicellular enemies of insects use to kill insect pests?
Once the entomologist has identified those proteins and
peptides, they become candidates for genetic engineering
into crops. Needless to say, the proteins and peptides
should enjoy some specificity and be insecticides and not
be fatal to man. Also, they should not decrease crop
yield. The introduction of those genes into crops offers
the promise of insect resistance in key crops, a dream of
the plant breeder.
Similar opportunities exist for fungicides and nema-
tocides. What genes must be transferred to a plant to
endow it with resistance to bacteria, fungi, insects, or
nematodes? Here too the pests of pests may hold the
clues. The pests of fungi, bacteria, and nematodes pro-
duce proteins, peptides, and other molecules that kill
fungi, bacteria and nematodes.
How far are we from the prospect of genetically engi-
neering a plant to resist insects? Three years ago I would
have guessed 15 or 20 years. Recent dramatic advances in
the transformation of plant cells, however, suggest a
much shorter time frame. There has been great progress
in the use of the microorganism, Agrobacterium tume-
fariens, a soil bacterium that can introduce genetic infor-
mation into plant cells while it creates tumors called
crown gall tumors. The Ti plasmid carried in this bacte-
rium has been engineered to disarm its tumorogenicity
and yet maintain its ability to insert appropriate genes
into plant cells in order to confer, for example, insect
resistance to the cells.
It appears likely that the genetic engineering of plants
will move forward rapidly, with crops engineered to be
resistant to insects and other pests becoming available by
the 1990s. Instead of treating crops with traditional pes-
ticides, in some important cases it will be possible to
endow the crop with pest resistance.
GENE O R G A N I Z A T I O N AND REGULATION IN
PLANTS. The application of genetic engineering in ag-
riculture will have enormous impact in the future, but
there are a number of impediments to rapid advance-
ments in the field. One of the most serious problems is
the lack of fundamental knowledge about gene or-
ganization and regulation in higher organisms such as
plants. It is not known what turns genes on and off at
specific times. Second, only about 25 of the many tens
of thousands of genes in a higher plant cell have been
characterized. Third, there is a large gap in the un-
derstanding of the basic biochemical mechanisms that
regulate the growth, development, and reproduction
of plants. In addition, the technology of tissue culture
still requires study so that a greater number of economi-
cally important plants can be regenerated from either
protoplast or cell systems. There is no doubt that the
application of molecular biological approaches to plant
research will expand knowledge about how genes are
organized and regulated, both temporally as well as
spatially, and will lead to considerable improvements in
crop production.
AN ENLARGED MISSION FOR AGRICULTURE. The
ability to genetically engineer plants will enlarge the
mission of agriculture. Agriculture today focuses prin-
cipally on food and fiber. But if plants can be genetically
engineered to produce animal proteins, other prospects
emerge. What if plants could produce human insulin or
human blood factors for hemophilia or a vaccine? Perhaps
the high-value-added crops of the 1990s will be plants
that produce drugs for human diseases. Perhaps human
insulin can be harvested from the "north forty" instead
of from huge fermentation tanks of genetically en-
gineered E. coli.
Another likely consequence of the genetic engineering
of plants, although one that is further in the future, is the
development of new crops designed not to produce food
or fiber, but to produce feedstocks for the world's chemi-
cal industry. Unlike the other scenarios discussed, this
one is not likely to occur on a broad scale until well after
the turn of the century because of the continued avail-
ability of petrochemical feedstocks and methanol from
natural gas. Indeed, the nearly universal consensus is
that, contrary to earlier predictions, the world's oil and
natural gas will last longer than had been predicted,
certainly well into the fourth decade of the next century,
if not longer. However, eventually these fossil fuels will
be depleted, and renewable resources will be required.
Today latex from rubber plants, oil from palms and oil
seeds, starch, molasses, sugar, cellulose, and lignin are
the principal, moderately large, chemical feedstocks de-
rived from agriculture. By the end of the century, how-
ever, crops will be developed that can produce other
chemical feedstocks for the world's chemical industries.
When that occurs, agriculture will have a broader market
for its crops.
GENETICALLY ENGINEERED SOIL BACTERIA. A sec-
ond aspect of biotechnology that is of potential import-
ance to agriculture is the development of genetically
engineered soil bacteria to enhance crop yields. Such
genetically modified bacteria would be added to the soil
or to seeds. Most plants live in loose association with
microorganisms, forming biological partnerships. One
partner is the familiar green plant such as the soybean
or corn. The other tiny partners are the soil bacteria
and fungi that may be intimately associated with the
root system of the plant and act as "middle men" in
transferring nutrients from the soil to the plant. Some of
the organisms live near the roots of the plant; others
actually invade the roots.
Bacteria that invade the roots of soybeans and "fix"
nitrogen there to the benefit of the soybean plant are
familiar examples. Much attention has been paid to these
nitrogen-fixing soil bacteria that convert atmospheric ni-
trogen to ammonia and reduce the need for fertilizer. But
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there are numerous other opportunities for using soil
microorganisms that could make obsolete some of today's
pesticides and fertilizers. For example, increased atten-
tion is being paid to the genetic engineering of soil
microbes to protect the roots of plants from insects,
disease, and viral attack. One strategy is to develop mi-
crobes that secrete natural chemicals capable of killing
pathogenic organisms and insects. Such a strategy could
have considerable potential to protect plant roots with
minimal environmental impact.
The use of genetically engineered microbes instead of
chemicals or soil amendments for crop protection prom-
ises to be of great value in both highly mechanized,
high-performance agriculture as well as in more labor-
intensive agriculture. Microbial pesticides are particu-
larly attractive because they will be less capital-intensive
than many of the products traditionally used in agricul-
ture. This will facilitate the introduction of such prod-
ucts into the agriculture of less developed countries. This
biological approach to selectively controlling insects and
other pests and to enhancing crop yields is likely to be a
critical component of crop protection and yield enhance-
ment in the future.
BIOTECHNOLOGY AND COMMODITY CHEMICALS
TODAY. What can be said about the application of
biotechnology to the production of large-volume, com-
modity chemicals? Can a biomass refinery be built that
would take in millions of pounds of cellulosics like wood
chips, corn stover, or bagasse and convert them to useful
large-volume chemicals? The prevailing opinion today is
that, although biomass conversion processes are now
technically feasible, they are not economical for most
countries. Biomass simply cannot compete as a pet-
rochemical feedstock today nor with methanol from coal
(U.S. Dept. of Commerce 1984).
By 2000 A.D., there will be biomass refineries in
Brazil as well as other developing countries where there
are special local opportunities to use cellulosic agricul-
tural wastes such as bagasse, or where rapidly growing
trees can be cultured and harvested. As time goes on,
more and more biomass use will occur. As mentioned
earlier, it is widely believed that most of the useful petro-
leum reserves on earth will be used up within 75 years,
and that the world must learn to depend on renewable
resources. In developing nations today, the use of agri-
culture for energy production must be second to food
production. It is a delicate balancing act. Also, it is
important to realize that more than a billion people today
use firewood as their principal energy source.
In developed countries such as the United States,
Western Europe, and Japan, there may be a new driving
force for chemicals produced via biotechnology. By and
large, such chemicals are environmentally safer to make.
Molasses or starch is a far more attractive and less haz-
ardous feedstock than are most chemical feedstocks based
on petrochemicals. There may be an incentive to develop
new processes for certain major bulk chemicals based on
biotechnology. However, today the outcome is uncertain.
How readily are biotechnology products and bio-
technology processes transferable to developing coun-
tries? Inventions do not improve the human condition
until they are applied. It has not escaped notice that
poliomyelitis still takes an enormous toll in many devel-
oping countries despite the existence of a reliable, one-
time vaccination. However, here are some viewpoints
to consider:
1) Almost any developing nation can make use of
genetically engineered seeds and root-colonizing mi-
crobes. This kind of biological control of pests can en-
hance yield and eliminate importing petrochemically
based agricultural chemicals.
2) A key need for the future is the development of
agricultural testing stations where the use of products
that enhance crop yields can be demonstrated and
explained.
3) The introduction of disease-resistant and more effi-
cient domestic animals is feasible.
4) New one-time vaccination processes, first for ma-
laria, then for trypanosome-borne diseases, and then for
the much tougher parasitic worms will be developed to
meet the needs of the Third World.
5) Biotechnology is not highly capital-intensive, for
the most part. Unlike many industrial processes re-
quiring expensive feedstocks and sophisticated manu-
facturing processes, biotechnology can be practiced with
limited resources. However, it does require an in-
frastructure, sources of equipment, repairs, and chemi-
cals at about the same level as a medium sized Western
hospital.
Despite the publicity that genetic engineering gets, its
pending impact on society and its durability as a sci-
entific tool in the service of humanity are under-
estimated. Indeed, it can be argued persuasively that
genetic engineering may turn out to be the most signifi-
cant scientific and technological discovery ever made.
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